COVID-19 Study of Safety and Tolerability of Alvelestat
Status:
Active, not recruiting
Trial end date:
2021-09-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety, tolerability and pharmacokinetics (PK),
and explore the mechanistic and clinical effect of alvelestat (an oral neutrophil elastase
inhibitor) orally twice per day for 10 days added to standard of care in adult patients (≥18
years) with COVID-19 respiratory disease.